Vermillion (NASDAQ:VRML) posted its earnings results on Thursday. The company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04), Morningstar.com reports. Vermillion had a negative return on equity of 201.03% and a negative net margin of 398.14%. The company had revenue of $0.77 million during the quarter.
Shares of VRML remained flat at $$0.57 during midday trading on Friday. The stock had a trading volume of 103,021 shares, compared to its average volume of 90,666. Vermillion has a 12 month low of $0.45 and a 12 month high of $2.10. The company has a debt-to-equity ratio of 0.11, a current ratio of 5.74 and a quick ratio of 5.70.
In other news, CEO Valerie Barber Palmieri bought 97,000 shares of the company’s stock in a transaction dated Friday, August 17th. The stock was bought at an average price of $0.52 per share, with a total value of $50,440.00. Following the completion of the acquisition, the chief executive officer now owns 178,063 shares of the company’s stock, valued at $92,592.76. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Robert Harry Beechey bought 75,000 shares of the company’s stock in a transaction dated Thursday, August 23rd. The shares were purchased at an average cost of $0.61 per share, with a total value of $45,750.00. The disclosure for this purchase can be found here. In the last three months, insiders have bought 291,100 shares of company stock valued at $157,931 and have sold 33,473 shares valued at $16,837. 4.25% of the stock is currently owned by company insiders.
TRADEMARK VIOLATION WARNING: “Vermillion (VRML) Releases Earnings Results, Hits Expectations” was originally posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/11/10/vermillion-vrml-releases-earnings-results-hits-expectations.html.
Vermillion Company Profile
Vermillion, Inc, together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women primarily in the United States. The company's diagnostic tests include OVA1, a blood test for the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor; and Overa, a multivariate index assay second generation test to determine the malignancy of ovarian cancer in women.
Featured Story: Stock Split
Receive News & Ratings for Vermillion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vermillion and related companies with MarketBeat.com's FREE daily email newsletter.